Heart failure & cardiomyopathiesRandomised controlled trial
Multicentre, Randomized, Double-Blind, Prospective Study on the Effects of ImmunoAdSorptiOn on Cardiac Function in Patients with Dilated CardioMyopathy (IASO-DCM): Rationale and Design
- Randomised controlled trial (rationale and design)
- multicentre
- double-blind
- placebo-controlled
- parallel-group
- 1:1 randomisation
Follow-up by telephone at 1 and 3 months and at study centres at 6, 12 and 24 months · Main secondary outcome: composite of all-cause death, cardiac resuscitation, HF hospitalisation and cardiac surgery to improve pump function at 24 months · Secondary: Left ventricular (LV) end-diastolic and end-systolic volumes over the study period
Authors' conclusion
IASO-DCM is a randomized study which will provide comprehensive insights into the effects of immunoadsorption with subsequent IgG substitution in patients with DCM.
Study context
- Population
- Patients with HF due to dilated cardiomyopathy (DCM) (LVEF <40%) on optimised guideline-directed HF medicationplanned
- Participants
- 200 patients
- Comparison
- Immunoadsorption with subsequent IgG substitution vs pseudo-treatment
- Primary endpoint
- Change in LVEF by contrast echocardiography (core lab)
- Follow-up
- Baseline to 6 months
Original publication
Multicentre, Randomized, Double-Blind, Prospective Study on the Effects of ImmunoAdSorptiOn on Cardiac Function in Patients with Dilated CardioMyopathy (IASO-DCM): Rationale and Design. Eur J Heart Fail. Published 2 October 2024. doi:10.1002/ejhf.3476
Summarised from the published abstract; every number is checked against it